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Synopsis
Expression of hTS (human thymidylate synthase), a key enzyme in thymidine biosynthesis, is regulated on the
translational level through a feedback mechanism that is rarely found in eukaryotes. At low substrate concentrations,
the ligand-free enzyme binds to its own mRNA and stabilizes a hairpin structure that sequesters the start codon. When
in complex with dUMP (2′-deoxyuridine-5′-monophosphate) and a THF (tetrahydrofolate) cofactor, the enzyme adopts
a conformation that is unable to bind and repress expression of mRNA. Here, we have used a combination of X-ray
crystallography, RNA mutagenesis and site-specific cross-linking studies to investigate the molecular recognition of
TS mRNA by the hTS enzyme. The interacting mRNA region was narrowed to the start codon and immediately flanking
sequences. In the hTS enzyme, a helix–loop–helix domain on the protein surface was identified as the putative
RNA-binding site.
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INTRODUCTION
Cellular DNA synthesis critically depends on the supply of
nucleotide triphosphate building blocks. The only de novo
biosynthetic pathway to generate dTTP (2′-deoxythymidine-
5′-triphosphate) requires reductive methylation of dUMP (2′-
deoxyuridine-5′-monophosphate) to dTMP (2′-deoxythymidine-
5′-monophosphate) by TS [1]. The TS enzyme is an obligatory
homodimer [2] whose subunits associate with nanomolar affinity
[3] to form a dimer that adopts an asymmetric conformation upon
substrate binding [4,5]. Inhibition of TS leads to the cessation of
DNA replication and thymineless death of proliferating cells [6],
which renders the enzyme an attractive target for cancer chemo-
therapy [7]. TS inhibitor drugs include 5-FU (5-fluorouracil),
which was one of the earliest anti-cancer agents and is still used
in the treatment of colorectal cancer [8,9]. 5-FU is metabol-
ized to FdUMP (5-fluoro-dUMP) which covalently modifies the
TS active site, forming a ternary complex that also contains the
methylene-THF (tetrahydrofolate) cofactor [7]. Other drugs that
target TS, for example raltitrexed, compete directly with the bind-
ing of the THF cofactor [10].
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The clinical use of TS inhibitors is limited by emerging tu-
mour resistance which arises from an increase in TS protein
levels. Among the mechanisms leading to rising the TS levels are
reduced turnover and increased the stability of the protein in the
presence of enzyme–inhibitor complexes and the up-regulation
of TS expression [6,7,11–13]. The increase in TS expression oc-
curring during 5-FU chemotherapy has been associated with an
autoregulatory mechanism of translation control for the enzyme
[14]. Ligand-free TS protein binds its own mRNA and thereby
represses translation [15,16]. Complex formation with the dUMP
substrate or inhibitors, including FdUMP abolishes mRNA bind-
ing of TS [17]. Therefore increased levels of TS expression are
observed during chemotherapy with 5-FU despite inactivation of
the enzyme, which ultimately results in emergence of tumour
resistance. Feedback regulation by protein binding to mRNA is
a common mechanism of translational regulation in bacteria, but
rare in eukaryotes. The TS system represents the first known
example of translational autoregulation in human [18].
In the TS system, full translational repression is caused by
protein binding at two mRNA sites [16]. One of the TS-binding
sequences (site 2) resides in an extended region of 200 nucle-
otides in the mRNA-coding region. The site 1 is predicted to fold
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
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into a stem loop structure that contains the translation initiation
site (Figure 1) [15]. TS protein binding to the regulatory mRNA
site 1 motif likely stabilizes the hairpin loop that renders the
start codon unavailable for ribosomal recognition. In a previous
investigation we had demonstrated that the TS site 1 hairpin con-
stitutes an autonomous regulatory RNA motif that maintains its
function when transplanted into heterologous reporter systems
[19]. From mutational and mechanistic studies of the TS site
1 motif we concluded that secondary structure of the RNA by
itself provides only a marginally stable roadblock to ribosomal
initiation, whereas binding of the TS protein reduces translation
initiation by sequestration of the start codon. Here, we have used
a combination of X-ray crystallography, in vitro translation func-
tional studies and UV cross-linking to investigate the molecular
recognition of the TS site 1 RNA motif by the enzyme.
EXPERIMENTAL
Reagents
Restriction nucleases, ligases and competent cells were from New
England Biolabs, plasmid purification kits from Promega and
restriction digest clean-up kits from Qiagen. Ni Sepharose 6 Fast
Flow was from General Electric. Salts, 2-mercaptoethanol, 37 %
(v/v) formaldehyde, imidazole, DTT, THF, Tris and acetonitrile
were from Sigma. CHAPS was from Thermo Fisher Scientific.
LB (Luria–Bertani) broth extract was from Becton, Dickinson
and Company. IPTG (isopropyl β-D-thiogalactopyranoside) and
ampicillin were from Research Products International. 5-FU was
from MP Biomedicals. Amicon Ultra-15 Centrifugal Filter Units
were from Millipore. All experiments were conducted in ultra-
pure RNase-free water.
Nucleic acids and hTS (human thymidylate
synthase) protein
DNA oligonucleotides for cloning and TS site 1 RNA for binding
studies as well as 4-thiouridine-modified RNA for cross-linking
were chemically custom-synthesized by Integrated DNA Tech-
nologies. Hexahistidine tagged hTS protein was expressed in
Escherichia coli and purified by chromatography over an Ni2 +
affinity column as described previously [19]. Bacterial TS was
removed by an additional wash step adding 10 column volumes
of 1 % (v/v) CHAPS buffer. The hTS protein was eluted on a
linear gradient of 40–100 mM imidazole. Eluted fractions were
run on an SDS–10%PAGE to ascertain purity. Fractions were
pooled, concentrated and dialysed into 20 mM Tris pH 8, 1 mM
DTT. The enzyme was stored for extended periods at − 80 ◦C.
Native PAGE of protein–RNA complexes
Precast Expedeon PAGE (8 % gel) were used for native PAGE
analysis of hTS–RNA complexes. The electrophoresis buffer
contained 50 mM Mops, pH 7.0 and 1 mM DTT. Samples were
loaded in a 1:1 mixture with 2× native loading buffer containing
40 mM Mops, pH 7.0, 4 mM DTT and 4 mM MgCl2. RNA was
visualized with SYBR® Gold nucleic acid stain.
Crystallography, data collection and structure
determination
Crystallization was performed by hanging drop vapour diffusion
at room temperature (22 ◦C) with hTS protein and TS1-33 RNA,
pre-incubated together at 150 μM concentration, in the presence
of either 1.75 M ammonium sulfate, 0.1 M Tris, pH 8.25, 20 mM
2-mercaptoethanol (‘high salt’) or 30 % PEG [poly(ethylene
glycol)] 1500 0.1M Tris, pH 8, 20mM 2-mercaptoethanol and
3 % (w/v) 1,5-diaminopentane dihydrochloride (‘low salt’). The
final drop volume was 2–4 μl. Crystals appeared within 24 h, and
grew to full size within 3–5 days. Crystals were flash-frozen in li-
quid nitrogen before data collection. Diffraction data were collec-
ted in a nitrogen stream at 110 K on a Rigaku MicroMaxTM 007
HF rotating anode X-ray generator (λ = 1.54 ˚A) equipped with
VariMax optics and a MAR345 imaging plate detector system.
Datasets collected were processed, integrated and scaled with
the HKL2000 package [20]. Structures were solved by molecular
replacement with the program Phaser [21] using search models
derived from published hTS coordinates [22,23] and refined by
the program Refmac [24] both within the CCP4 package [25].
Subsequent iterative rounds of manual building and refinement,
alternating between Refmac and manual rebuilding in Coot [26],
were based on the obtained 2Fo–Fc and Fo–Fc maps. Positions of
sulfate ions were initially assigned based on electron density as
well as geometry of coordinating ligands. Final refinement was
carried out in PHENIX [27] with individual isotropic atomic dis-
placement parameters and water picking (Supplementary Tables
S1 and S2). Coordinates and structure factors for the hTS protein
have been deposited in the RCSB PDB under accession codes
4H1I (low salt structure) and 4GYH (high salt structure).
Bicistronic reporter constructs for IVT (in vitro
transcription)–translation
Cloning of bicistronic reporter constructs TS1-wt (wild-type) and
TS1 (Supplementary Figure S4) was performed as described
previously [19]. The TS1-wt construct was used as the starting
material for preparation of the TS1-xx truncation mutants, whose
sequences are shown in Figure 1, by QuickChange Mutagenesis
according to manufacturer’s protocol (Agilent). Mutations were
introduced by synthetic oligonucleotide primers that contained
the desired truncated TS1 hairpin and 12 complementary nucle-
otides upstream and downstream of the mutation site. The non-
complementary sequences inserted into the respective constructs
are listed in the Supplementary Table S5. The integrity of reporter
constructs carrying TS1-xx truncation mutants was confirmed by
sequencing.
IVT-translation assay and luciferase detection
The IVT assay using bicistronic luciferase reporter constructs
(Figure 3) was performed as described previously [19]. For ex-
periments in the presence of hTS, protein was added from stock
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solution to achieve a final concentration of 5 μM in the IVT
reaction mixture. No other modifications were made.
Cross-linking of hTS–RNA complexes
The cross-linking of the hTS protein to the TS1–33 and TS1–14
RNAs was conducted at room temperature (22 ◦C). Concentra-
tions of the protein and the RNA were 200 μM each in the initial
cross-linking experiments (Figures 4A and 4B), and 25 μM pro-
tein with 10 μM RNA in the time course analysis (Figure 4C). The
final buffer conditions contained 10 mM Hepes, pH 7.0, 100 mM
NaCl, 2 mM DTT and 10 % (v/v) glycerol. The hTS–RNA com-
plex was kept on ice for 5 min prior to exposure to UV light at a
wavelength of 360 nm. After UV exposure of 10 min (Figures 4A
and 4B) or the designated time points in the kinetic analysis (Fig-
ure 4C), samples were conserved on ice until their subsequent
loading on a polyacrylamide gel. After electrophoretic separa-
tion for 30–60 min, the protein was visualized using SimplyBlue
SafeStain (Invitrogen). As a control, samples of hTS in the ab-
sence of RNA were cross-linked and analysed identically.
Protease digestion of cross-linked hTS–RNA
complexes
MS analysis of peptide fragments was performed following es-
tablished procedures [28]. Slices of PAGE from electrophoretic
separation containing cross-linked complex, or free hTS as a con-
trol, were cut to 1 mm×1 mm cubes and destained three times
by first washing with 100 μl of 100 mM ammonium bicarbonate
for 15 min, followed by addition of the same volume of acet-
onitrile for 15 min. The supernatant was removed and samples
were dried in a speedvac. Samples were then transferred to redu-
cing conditions by mixing with 200 μl of 100 mM ammonium
bicarbonate and 10 mM DTT, and incubated at 56 ◦C for 30 min.
After removal of the liquid, 200 μl of 100 mM ammonium bicar-
bonate and 55 mM iodoacetamide was added to gel pieces and
incubated at room temperature (22 ◦C) in the dark for 20 min.
After the removal of the supernatant and one wash with 100 mM
ammonium bicarbonate for 15 min, an equivalent volume of acet-
onitrile was added to dehydrate the gel pieces. The solution was
then removed and samples were dried in a speedvac. For pro-
tease digestion, enough solution of ice-cold trypsin (0.01 μg/μl)
in 50 mM ammonium bicarbonate was added to cover the gel
pieces, and then kept on ice for 30 min. After complete rehydra-
tion, the excess trypsin solution was removed, replaced with fresh
50 mM ammonium bicarbonate, and left overnight at 37 ◦C. Pep-
tides were extracted twice by the addition of 50 μl of 0.2 % (v/v)
formic acid and 5 % (v/v) acetonitrile followed by vortexing at
room temperature (22 ◦C) for 30 min. The supernatant was re-
moved and preserved. A total of 50 μl of 50 % acetonitrile–0.2 %
formic acid was added to the sample, which was vortexed again
at room temperature for 30 min. The supernatant was removed
and combined with the supernatant from the first extraction. The
combined extraction solutions were analysed directly by HPLC)
coupled with MS/MS (tandem MS) using ESI (electrospray ioniz-
ation). As a control, UV-irradiated samples of hTS in the absence
of RNA were analysed identically.
MS analysis of proteolytic peptides from
cross-linked hTS–RNA complexes
ESI of peptide fractions was performed using a TripleTof 5600
hybrid mass spectrometer (ABSCIEX) interfaced with nano-
scale RP-HPLC (reverse-phase HPLC) (Tempo) using a 10 cm–
100 μm ID glass capillary packed with 5 μm C18 ZorbaxTM
beads (Agilent). Peptides were eluted from the C18 column into
the mass spectrometer using a linear gradient (5–60 %) of acet-
onitrile at a flow rate of 250 μl/min for 1 h. The buffers used
to create the acetonitrile gradient were: buffer A, 98 % H2O,
2 % acetonitrile, 0.2 % formic acid and 0.005 % TFA (trifluoro-
acetic acid); buffer B, 100 % acetonitrile, 0.2 % formic acid and
0.005 % TFA. MS/MS data were acquired in a data-dependent
manner in which the MS1 data were acquired for 250 ms at m/z
of 400–1250 Da and the MS/MS data were acquired from m/z of
50–2000 Da. The IDA (independent data acquisition) paramet-
ers were MS1-TOF (time-of-flight) 250 ms, followed by 50 MS2
events of 25 ms each. The IDA criteria were, over 200 counts
threshold, charge state + 2–4 with 4 s exclusion. The collected
data were analysed using MASCOT® (Matrix Sciences) and Pro-
tein Pilot 4.5 (ABSCIEX) for peptide identification. Peakview
(ABSCIEX) was used for peptide quantification analysis. For
this analysis the m/z corresponding to each peptide was extracted
from the MS1 chromatogram and the area under the peak was
determined. Peak areas for the peptides that showed no change
in their relative area were used to normalize different chroma-
tograms analysed in these experiments. As a control for peptide
abundance, samples of hTS UV-irradiated in the absence of RNA
were analysed identically.
RESULTS
Crystallization and structure determination of hTS
in the active and inactive conformation
To gain direct insight into the molecular recognition of mRNA by
hTS, we attempted co-crystallization of the enzyme with oligo-
nucleotide constructs representing the TS site 1 motif (Figure 1).
Diffracting crystals were obtained at varying salt conditions for
hTS in the presence of the 33 nt RNA construct TS1-33 which
binds the hTS protein (Supplementary Figure S1. The TS1–33
RNA covers nucleotides 80–112 of the TS site 1 motif and largely
overlaps with a 36 residue oligonucleotide (‘35-TS’) spanning
the sequence of positions 75–110, which is a previously reported
minimal oligonucleotide construct shown to bind hTS [15]. X-
ray data sets were collected and structures determined for crystals
grown at low salt (100 mM buffer) as well as high salt (1.75 M
ammonium sulphate) concentration (Supplementary Tables S1
and S2). Molecular replacement with previously published hTS
coordinates furnished structures with the enzyme adopting either
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Figure 1 Secondary structure of the TS1 (thymidylate synthase-
binding site 1) in the mRNA of the human enzyme
TS binding sequesters the AUG initiation codon. A second TS-binding
site is located within the reading frame. Arrows mark the boundaries
of truncated TS1 motifs (TS1-X, where X indicates the length) which
were used for in vitro translation, co-crystallization and cross-linking
experiments described in this study. Numbering is according to the
Homo sapiens sequence, record NM_001071 of the NCBI Nucleotide
Database.
of the previously observed active and inactive conformations of
the loop regions about I108-G129 and A181-A197 (Figure 2 and
Supplementary Table S3); however, each without RNA bound. In
the active conformation, the catalytic C195 is located in the active
site, while it resides at the dimer interface in the inactive conform-
ation. The structure of hTS obtained at high salt (PDB: 4GYH)
was nearly identical to a previously published crystal structure of
the enzyme in the inactive conformation in a complex with the
allosteric inhibitor PDPA (1,3-propanediphosphonic acid) (PDB:
2ONB) [23]. The hTS structure determined at low salt (PDB:
4H1I) represents the first time that the ligand-free protein has
been captured in the active conformation, which was previously
observed only in a mutant containing the stabilizing mutation
R163K (PDB: 2RD8) [29] and in substrate complexes, includ-
ing a ternary complex of the enzyme with dUMP as well as the
folic acid analogue inhibitor raltitrexed (PDB: 1HVY) [30]. The
structure of the hTS active conformation in 4H1I is essentially
identical to the structure of the R163K variant (Supplementary
Figure S2 and Supplementary Table S3). In both the low and high
salt structures 4GYH and 4H1I, a sulfate ion was located at the
position of the dUMP phosphate group in the ternary complex.
A second sulfate was present in the high salt structure coinciding
with the location of a phosphate from the PDPA inhibitor in the
published inactive conformation (PDB: 2ONB) [23]. Apart from
the previously observed conformational distinction around the
loop I108-G129, the peptide K107-E128 was disordered in the
high salt structure but adopted a well-defined helix–loop–helix
Figure 2 Superposition of hTS structures
The protein structures were determined by X-ray diffraction from crys-
tals grown at low (green, PDB code 4H1I) and high (grey, PDB code
4GYH) salt conditions. Only one subunit of the hTS dimer is shown. The
K107–E128 peptide, which is disordered in the high salt structure, is
highlighted in dark green in the low salt structure. The flanking ordered
residues V106 and G129 are indicated by spheres in both structures.
Two sulfate ions which are part of the high salt structure are shown in
grey, one sulphate in the low salt structure is shown in green.
motif in the low salt structure (Figure 2) as previously observed
in the R163K mutant [29] and the ternary complex (PDB: 1HVY)
[30].
The structures of hTS observed in the crystals grown at low
and high salt conditions do not reveal why the TS1-33 RNA
failed to co-crystallize with the protein. Previously, it had been
proposed that hTS functions as a metabolic enzyme in the active
conformation but as a nucleic acid-binding protein in the inactive
state [12]. Structure comparison of native and substrate-liganded
hTS suggested that nucleic acid-binding might be achieved in the
inactive but not the active conformation of the enzyme [22,30]. In-
spection of the crystal structure of hTS in the active state, which
we obtained at low salt conditions (PDB: 4H1I), revealed that
packing of the protein dimers in the crystal involves the surface
including a helix–loop–helix motif around residues G84-K104.
As outlined below, cross-linking studies with TS site 1 RNA in-
dicate that the same helix–loop–helix motif provides the nucleic
acid-binding site of hTS (Supplementary Figure S3). Crystalliz-
ation of hTS at low salt may have led to discrimination against
RNA ligand binding by crystal contacts that involve the putative
RNA-binding region.
The hTS enzyme recognizes the apical hairpin of
the TS site 1 mRNA motif
To better define the binding site of hTS on the mRNA motif, we
investigated the function of TS site 1 truncation mutants in which
parts of the stem region were deleted. The impact of the deletions
was studied using a coupled IVT-translation assay that measured
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Figure 3 Luciferase reporter translation under the control of the TS1 regulatory element
Translation levels are shown for the wt TS1 element (TS1-wt) and truncated versions (TS1-23, 20, 15) in the absence
and presence of the hTS enzyme. As a comparison, the expression is shown from a construct lacking the TS1 motif
(TS1). Construct structures are shown in the Supplementary Figure S3. For experiments in the presence of hTS ( + )
the recombinant enzyme was added at 5 μM concentration. Expression from TS1 constructs (TS1-23, 20, 15) in the
absence of protein ( − , white columns) was normalized to the wt motif (TS1-wt) to demonstrate the increase of translation
efficiency with decreasing stability of the TS1 truncation variant. Expression in the presence of hTS ( + , grey columns)
was normalized for each TS1 construct to its own translation efficiency in the absence of protein to indicate the relative
decrease caused by hTS binding on a scale from 0 to 1. Data are averages of three replicates with error bars showing
+−1σ .
protein expression by quantitation of luminescence from a lu-
ciferase reporter. A previously established bicistronic construct
carrying firefly luciferase under the control of the TS site 1 motif
and an internal ribosome entry site-driven Renilla luciferase as
a TS-independent internal standard [19] (Supplementary Figure
S4) was modified to furnish three stem-truncation mutants, in-
cluding TS1–23, TS1–20 and TS1–15 (Figure 1). Truncations
were chosen to maintain the pyrimidine-rich flanking sequences
around the initiation codon as well as the reading frame of the
luciferase reporter. The T1–15 construct was the shortest vari-
ant that still maintained a hairpin secondary structure around the
start codon. As we had demonstrated previously, addition of hTS
inhibits reporter expression from the TS1-wt construct because
of the protein binding to the TS site 1 RNA motif and thereby
sequestering the start codon [19]. Expression from a control con-
struct, TS1, which does not contain the TS regulatory motif, is
unaffected by the presence of hTS. As expected, translation effi-
ciency of the truncation mutants in the absence of hTS increased
relative to TS1-wt in correlation with the lower stability of the
truncated variants, illustrating how less stable hairpin secondary
structures present a smaller energy barrier to overcome by the
translation machinery. However, in the presence of the hTS pro-
tein, all three TS1 truncation mutants showed reduced reporter
expression (Figure 3). This suggests that sequences immediately
flanking the start codon in the apical hairpin loop of the TS site
1 RNA are sufficient for interaction with the hTS protein, while
the lower stem region may play a subordinate role. Importantly,
the C85–C105 mismatch (Figure 1), which has been proposed
as a key determinant of small molecule ligand binding to the
TS site 1 RNA [31,32], is not an absolute requirement for hTS
binding as none of the truncation mutants contained this mo-
tif. This is consistent with our previous finding that a TS site
1 RNA mutant in which the C85–C105 mismatch was replaced
by a G85–C105 base pair was still able to bind the hTS protein
[19].
Site-specific cross-linking reveals the site 1 RNA
binding site in hTS
To identify the interacting regions in the complex of hTS and TS
site 1 RNA, we performed cross-linking experiments guided by
IVT studies of RNA truncation mutants, which suggested that
the start codon and immediately flanking sequences may provide
a binding site for the protein. Two RNA constructs, including
the TS1–33 oligonucleotide used before in crystallization studies
and a shorter TS1–14 oligonucleotide (Figure 1), were chem-
ically synthesized with the U95 residue in the start codon re-
placed by 4-thiouridine [33]. Cross-linking was performed by
UV-irradiation of hTS in complex with the thiouridine-labelled
oligonucleotides. To limit covalent modification to thiouridine
residues and avoid non-specific cross-linking, UV at a wavelength
of 360 nm was used. Gel electrophoretic analysis of cross-linked
samples showed that the longer TS1–33 construct formed a single
defined complex with the hTS protein, while the TS1–14 oligo-
nucleotide gave rise to several distinct complexes, likely because
of multiple binding events of the smaller RNA (Figure 4A). It is
conceivable that 1:1 complex formation with the TS1–33 RNA
induces a conformational change in the hTS dimer such that bind-
ing of the cognate RNA motif at one subunit prevents the other
protein monomer from associating with RNA. A similar effect
had been observed in substrate and cofactor binding which occur
with negative co-operativity by the two subunits [34]. The ma-
jority of crystal structures reported for TS from human and other
organisms show a symmetric arrangement of subunits [35,36]
which does not support half-of-the-sites reactivity. However,
half-site occupation with ligands had been observed in struc-
tures of the Pneumocystis carinii TS and the human TS mutant
R163K [4,5]. The proposed half-site binding of the cognate RNA
ligand would be in agreement with the observation of a single
cross-linked complex for the TS1–33 RNA and may explain why,
even in the presence of excess TS1–33 RNA, the cross-linking
efficiency never exceeded 50 % of the available TS protein.
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Figure 4 Cross-linking of hTS protein with TS1 RNA constructs in which the start codon U95 was substituted by 4-
thiouridine
(A) Denaturing PAGE analysis of cross-linked complexes with TS1-33 and TS1-14 RNA (for RNA sequences see Figure 1).
Positions are indicated of the hTS monomer and dimer in the free form (m, d) and cross-linked (×m, ×d). Protein
dimer may be present due to incomplete denaturation (see Supplementary Figure S5). (B) Native PAGE analysis of hTS
cross-linked with TS1–33 RNA. Both protein and RNA were at 200 μM concentration. Free protein, cross-linked dimer (×d)
and monomer (×m) are indicated. Conditions marked by * contain 1 % zwitterionic detergent (CHAPS). (C) Native PAGE
analysis of a cross-linking time course of hTS protein and TS1–33 RNA. Protein and RNA concentrations were 25 and
10 μM, respectively. Free protein, cross-linked dimer (×d) and monomer (×m) are indicated.
Gel-electrophoretic analysis of complex from cross-linking of
hTS protein with TS1–33 RNA under native conditions (Fig-
ure 4B) demonstrates that formation of the protein–RNA complex
is compatible with both the hTS monomer and dimer, although
dimer was present in excess. Kinetic analysis by following cross-
linking over time suggested that the TS1–33 construct preferably
cross-linked with the hTS dimer (Figure 4C) which is the dom-
inating form of hTS in solution [3].
To identify domains of the hTS protein involved in TS1–33
RNA binding, we performed a qualitative MS analysis of pep-
tide fragments from the cross-linked protein. Cross-linked hTS–
TS1–33 complex in cut-out PAGE slices was digested by trypsin.
Peptide fragments from the protease treatment were separated by
LC (liquid chromatography) and identified with MS/MS. As a
control, hTS protein in the absence of RNA was UV-irradiated
under the same conditions as used for cross-linking and analysed
identically to the cross-linked samples. Abundance of peptide
fragments was calculated from the LC–MS/MS analyses and
compared with the unliganded protein and the cross-linked com-
plex (Supplementary Table S4). Peptides that were detected at
a reduced rate in the cross-linked complex correspond to hTS
domains that were either covalently modified by cross-linking
with the TS1–33 RNA or that were protected from trypsin diges-
tion because of conformational changes induced by RNA binding
(Supplementary Figure S6). We did not detect mass signals cor-
responding to peptides that were modified by RNA cross-linking,
however, and had to rely on observation of the abundance dif-
ferential to identify potential interaction sites. The absence of
signals for peptide–RNA conjugates was attributed to low ioniz-
ation efficiency of then negatively charged species.
The cross-linking and MS analysis of peptide fragments was
performed in triplicate and peptide abundance observations were
considered that occurred consistently in all three experiments.
When peptides with significantly decreased abundance in the
complex were mapped on the hTS crystal structure, a helix–
loop–helix motif (G84–K104) adjacent to the active site cleft
was identified as the likely cross-linking domain (Figure 5). In
the cross-linked complex, a peptide involved in a solvent-exposed
helix (G94–K104) was undetectable, and the abundance of a
preceding peptide involved in a second helix (G84–K93) was
reduced by about 150-fold. Abundances of peptides in adjacently
packing helices and a β-sheet in the core of the protein were
reduced as well, likely through indirect effects by RNA cross-
linking at the neighbouring helix–loop–helix motif. The G84–
K104 helix–loop–helix domain is located at the periphery of the
hTS fold with the G94–K104 helix protruding from the protein
surface. The helix involving residues G84–K93 has one face
exposed to solvent, while the other side provides a wall of the
active site cleft. The accessibility of the helix–loop–helix motif
on the protein exterior and cross-linking data are consistent with
a proposed function as the hTS RNA-binding site. However, the
sequence of the G84–K104 helix–loop–helix domain bears no
homology to known RNA-binding motifs, suggesting that hTS
recognizes the TS site 1 RNA via a unique structural element.
Deeper insight into details of the protein–RNA interaction will
require a crystal structure of the complex.
DISCUSSION
Here, we have used a combination of X-ray crystallography, RNA
mutagenesis and site-specific cross-linking studies to investigate
the molecular recognition of the site 1 motif in TS mRNA by the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
910 c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
mRNA recognition by human thymidylate synthase
Figure 5 Results from TS site 1 RNA cross-linking with hTS
Cross-linking results were mapped on the protein crystal structure determined at high salt conditions (grey, PDB code
4GYH) which corresponds to the RNA-binding inactive conformation of the enzyme. (A) Front view: MS analysis of proteolytic
fragments from the cross-linked hTS–RNA complex shows that cross-linking occurs at a helix–loop–helix motif adjacent to
the active site cleft. In the cross-linked complex, a peptide spanning the outer helix (G94–K104, red) was undetectable
and the abundance of the peptide involved in the inner helix (G84–K93, orange) was about 150-fold reduced. Two
lysine residues in the outer helix (K99, K104), which are likely cross-linking candidates, are highlighted in magenta stick
representation. Abundances of peptides in adjacent helices and a β -sheet in the core of the protein were reduced as
well (light orange), likely through indirect effects by RNA cross-linking at the neighbouring helix–loop–helix motif. (B) Side
view: superposition of hTS in the active conformation (blue, PDB code 1HVY) which had been crystallized in complex with
the folic acid analogue inhibitor raltitrexed (green) and dUMP substrate (cyan) covalently bound at the active site residue
C195. Only one subunit is shown for 4GYH, the dimer for 1HVY. Two sulfate ions shown are part of the 4GYH structure.
The K107–E128 peptide is disordered in the inactive conformation but well-ordered in the active conformation (dark blue).
The flanking ordered residues V106 and G129 are indicated by spheres in both structures. Two carboxylate groups of
raltitrexed are positioned in close proximity to the G84–K93 helix which cross-links to RNA.
hTS protein. Although the crystallography effort furnished struc-
tures of the protein in both the active and inactive conformation,
co-crystallization of an hTS–RNA complex remained elusive.
Mutagenesis studies of the TS site 1 motif in the context of
in vitro translation experiments and cross-linking of hTS–RNA
complexes allowed narrowing the interacting RNA region to the
start codon and immediately flanking sequences, mapping to the
apical loop of the TS site 1 RNA motif. In the hTS enzyme,
the helix–loop–helix domain spanning residues G84–K104 on
the protein surface was identified as the putative binding site for
TS site 1 RNA. Crystal structure analysis revealed that in the
cofactor and dUMP substrate-bound, active conformation of the
enzyme the G84–K104 helix–loop–helix motif is obstructed by
the K107–E128 peptide which adopts an ordered, predominantly
helical structure which may prevent RNA binding. In the inactive
conformation, the K107–E128 peptide is disordered and allows
ligand access to the G84–K104 helix–loop–helix motif. Inter-
estingly, while TS is highly conserved among eukaryotes and
prokaryotes, an insertion of 12 residues within the K107–E128
peptide (at position 117) and a second insertion of eight residues
at position 148 are unique to eukaryotes and only the human en-
zyme has been found to bind its own mRNA at the initiation site
[1,37].
Without detailed insight into the structure of the protein–RNA
complex, it is not clear how RNA binding to one subunit affects
the other subunit in the hTS dimer. However, results from the
present study that led to the identification of the putative RNA-
interaction domain will guide future research including muta-
tional analysis of the helix–loop–helix motif in G84–K104 and
the conformationally flexible K107–E128 peptide. Quantitative
optimization of the hTS–RNA cross-linking approach outlined
here promises to provide covalently tethered complex for future
crystallization and X-ray diffraction studies, which will eventu-
ally yield a high-resolution picture of the hTS–RNA complex.
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